DK1815245T3 - Præmaturt ældende musemodeller til rollen som DNA-beskadigelse i ældning og intervention i ældningsrelateret patologi - Google Patents

Præmaturt ældende musemodeller til rollen som DNA-beskadigelse i ældning og intervention i ældningsrelateret patologi

Info

Publication number
DK1815245T3
DK1815245T3 DK05809080.4T DK05809080T DK1815245T3 DK 1815245 T3 DK1815245 T3 DK 1815245T3 DK 05809080 T DK05809080 T DK 05809080T DK 1815245 T3 DK1815245 T3 DK 1815245T3
Authority
DK
Denmark
Prior art keywords
aging
compounds
discovery
screening
current invention
Prior art date
Application number
DK05809080.4T
Other languages
English (en)
Inventor
Jan Hendrik Jozef Hoeijmakers
Der Horst Gijsbertus Theodorus Johannes Van
Wim Vermeulen
Roland Kanaar
George Aris Garinis
Steeg Harmen Van
James Robert Mitchell
Nicolaas Gerardus Josepth Jaspers
Laura Niedernhofer
Boer Jan De
Jaan Olle Andressoo
Der Pluijm Ingrid Van
Original Assignee
Erasmus Mc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1815245(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erasmus Mc filed Critical Erasmus Mc
Application granted granted Critical
Publication of DK1815245T3 publication Critical patent/DK1815245T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
DK05809080.4T 2004-11-15 2005-11-15 Præmaturt ældende musemodeller til rollen som DNA-beskadigelse i ældning og intervention i ældningsrelateret patologi DK1815245T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04078128 2004-11-15
PCT/NL2005/050043 WO2006052136A2 (en) 2004-11-15 2005-11-15 Prematurely ageing mouse models for the role of dna damage in ageing and intervention in ageing-related pathology

Publications (1)

Publication Number Publication Date
DK1815245T3 true DK1815245T3 (da) 2010-08-02

Family

ID=34928662

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05809080.4T DK1815245T3 (da) 2004-11-15 2005-11-15 Præmaturt ældende musemodeller til rollen som DNA-beskadigelse i ældning og intervention i ældningsrelateret patologi

Country Status (10)

Country Link
US (1) US20090077676A1 (da)
EP (3) EP2241884A3 (da)
JP (1) JP2008520200A (da)
AT (1) ATE465406T1 (da)
AU (1) AU2005302854B2 (da)
CA (1) CA2586157A1 (da)
DE (1) DE602005020832D1 (da)
DK (1) DK1815245T3 (da)
ES (1) ES2344957T3 (da)
WO (1) WO2006052136A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2035012A2 (en) * 2006-05-15 2009-03-18 Erasmus MC Mannitol and/or proline for prevention and treatment of ageing related symptoms
FR2924334B1 (fr) * 2007-11-30 2016-03-25 Lvmh Rech Composition cosmetique comprenant l'acide 2-glucoside ascorbique et l'ergothioneine.
US20100086941A1 (en) * 2008-10-01 2010-04-08 Adami Guy R Methods for determining aged based accumulation of senescent cells using senescence specific DNA damage markers
EP2367418A4 (en) * 2008-11-25 2012-04-18 Univ Rochester ANIMAL MODEL FOR OSTEOARTHRITIS AND BAND DISEASE
BRPI1009796A2 (pt) * 2009-03-30 2016-08-23 Shiseido Co Ltd composições para aliviar danos induzidos por irradiação ultravioleta
JP2012231786A (ja) * 2011-04-18 2012-11-29 Kyushu Univ 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法
US20190093163A1 (en) * 2015-06-12 2019-03-28 President And Fellows Of Harvard College Compositions and methods for maintaining splicing fidelity
US20170362394A1 (en) 2016-06-18 2017-12-21 Harsha Chigurupati Composition to Reduce DNA and Hepatic Damage and to Enhance Repair Thereof
WO2018061020A1 (en) 2016-09-30 2018-04-05 Chigurupati Harsha A composition for dna protection
CN109790993B (zh) * 2016-10-11 2021-08-17 三菱电机株式会社 空调装置
CN110729022B (zh) * 2019-10-24 2023-06-23 江西中烟工业有限责任公司 一种被动吸烟大鼠早期肝损伤模型建立方法及相关基因筛选方法
CN113293140A (zh) * 2021-05-25 2021-08-24 昆明理工大学 一种端粒酶阴性的小鼠alt细胞模型及其构建方法
WO2023221030A1 (en) * 2022-05-19 2023-11-23 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Use of ergothioneine to suppress deleterious effects of senescence
WO2024015594A1 (en) * 2022-07-15 2024-01-18 The Children's Medical Center Corporation Mouse model for retina degeneration and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9125198A (en) * 1997-08-28 1999-03-16 Thomas Jefferson University Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins
AU1415501A (en) * 1999-11-19 2001-06-04 Kyowa Hakko Kogyo Co. Ltd. Novel polypeptide, novel dna, novel anitbody and novel transgenic animal
AU2002232521A1 (en) * 2000-11-11 2002-05-21 Oregon Health & Science University Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
AU2002248262B2 (en) * 2000-12-21 2007-11-01 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of tumor senescence genes
US7041449B2 (en) * 2001-03-19 2006-05-09 Wisconsin Alumni Research Foundation Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice
DE10133202A1 (de) * 2001-07-07 2003-01-16 Beiersdorf Ag Osmolyte enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
NZ526350A (en) * 2003-06-09 2004-10-29 A Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol

Also Published As

Publication number Publication date
WO2006052136A3 (en) 2006-11-09
EP2218449A3 (en) 2011-05-18
WO2006052136A2 (en) 2006-05-18
EP2241884A3 (en) 2011-02-23
AU2005302854A1 (en) 2006-05-18
EP2218449A2 (en) 2010-08-18
JP2008520200A (ja) 2008-06-19
EP1815245B1 (en) 2010-04-21
AU2005302854B2 (en) 2012-01-12
CA2586157A1 (en) 2006-05-18
DE602005020832D1 (de) 2010-06-02
ATE465406T1 (de) 2010-05-15
ES2344957T3 (es) 2010-09-10
EP1815245A2 (en) 2007-08-08
EP2241884A2 (en) 2010-10-20
US20090077676A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
DK1815245T3 (da) Præmaturt ældende musemodeller til rollen som DNA-beskadigelse i ældning og intervention i ældningsrelateret patologi
NO20064358L (no) Svovelforbindelser som inhibitorer for hepatitt C-virum-NS3-serinprotease
WO2007059432A3 (en) Non-linear controller for switching power supply
NO20064357L (no) Nye forbindelser som inhibitorer for hepatitt C-virus-NS3-serinprotease
AR065984A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. composiciones farmaceuticas.
WO2007008758A3 (en) Methods for identifying agents and conditions that modulate neurogenesis
WO2012145624A3 (en) Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
NO20084490L (no) Nye forbindelser
WO2009073808A3 (en) Compositions and methods to modulate cell membrane resealing
DK201200196A (en) Imaging and evaulating embryos, oocytes, and stem cells
ECSP088254A (es) Compuestos activos en ppar
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
DK1869186T3 (da) Fremgangsmåde og midler til fjernelse af en udvalgt sekvens
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
TW200709841A (en) Method and system for purifying a gas
NO345120B1 (no) Fremgangsmåte for brønnhull, og apparatur for styring av sand og inngående strøm ved brønnoperasjoner
NO20082170L (no) Forbedret testosterongel og fremgangsmate til anvendelse
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
NO20083670L (no) Forbindelser og fremgangsmater for modulering av proteinomsetning
IL193846A0 (en) Methods for regulating inflammatory mediators and peptides useful therein
BRPI0615415A2 (pt) método para melhorar a capacidade de remoção de água de lodo
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
CL2007002546A1 (es) Compuestos derivados de 1,3-tiazol; composicion para controlar insectos que comprende uno de dichos compuestos; y metodo para controlar insectos que comprende aplicar dicho compuesto en el lugar donde se desea efectuar el control.
DE502005000071D1 (de) Verfahren zum Einstellen des Steuerstroms von stromgesteuerten Hydraulikventilen
TNSN08496A1 (en) Aminothiazoles and their uses